<DOC>
	<DOCNO>NCT01002781</DOCNO>
	<brief_summary>Patients adult 's Still disease suffer acute inflammatory symptom fever , arthritis , rash , acute phase response often require high dose corticosteroid . In view several case report show dramatic improvement patient treat Tocilizumab phase 2 study drug child Still 's disease , objective current study ass efficacy safety Tocilizumab patient adult 's Still disease .</brief_summary>
	<brief_title>Efficacy Safety Tocilizumab Adult 's Still Disease</brief_title>
	<detailed_description>This multicenter , open , study design investigate effect Tocilizumab , monoclonal antibody IL-6 receptor , management active adult-onset Still 's disease . Standard medication corticosteroid give patient discretion treat physician . Visits include : screening visit , week , week 2 , every 4 week 52 week After comply inclusion exclusion criterion , patient start treatment Tocilizumab dosage 8 mg/kg , every 2 week Patients assess every visit presence fever , tender swollen joint , rash , dosage corticosteroid DMARD 's , CRP ESR</detailed_description>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Still 's Disease , Adult-Onset</mesh_term>
	<criteria>Patients must diagnose adultonset Still 's disease accord criterion Yamaguchi ( least 5 criterion total , include least 2 major criterion ) , although criteria present time inclusion study . Major criterion : Fever ≥39°C least 1 week , Arthralgia last least 2 week , Maculopapular , nonpruritic skin rash , Leucocytosis .≥10,000/mm³ ) include ≥80 % neutrophil ; Minor criterion : Pharyngitis sore throat , Lymphadenopathy splenomegaly , Liver enzyme ( transaminase ) abnormality , Negative rheumatoid factor antinuclear antibody Patients age &gt; 18 Capable signing inform consent active infection ( especially sepsis EpsteinBarr virus ) , malignant disease ( especially lymphomas ) , autoimmune inflammatory disease ( especially polyarteritis nodosa ) patient require restrict treatment Still 's disease lowdose corticosteroid +/ non steroidal anti inflammatory drug least first 4 week study . pregnant breastfeed woman woman childbearing potential unwilling use adequate contraception become pregnant course study previous treatment biologic antirheumatic agent require washout period inclusion history listeriosis latent active tuberculosis persistent chronic active recur infection require treatment antibiotic , antiviral , antifungal within 4 week prior screen visit , history frequent recurrent infection unacceptable per investigator judgment . receive administration live ( attenuate ) vaccine within 3 month prior inclusion visit know history Human Immunodeficiency Virus antibody ; and/or positive Hepatitis B surface antigen , and/or positive Hepatitis C antibody screen visit . history recurrent herpes zoster . history prior articular prosthetic joint infection history hypersensitivity reaction , localise injection site reaction , biological molecule uncontrolled diabetes patient dialysis presence follow laboratory abnormality screen visit : haemoglobin &lt; 8.5g/l , WBC &lt; 3000/μL , platelet count &lt; 150,000/μL , neutrophil &lt; 1500/μL AST ALT &gt; 2 Upper limit bilirubin &gt; 2 Upper limit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Tocilizumab Still</keyword>
</DOC>